December 18, 2017 03:59 PM EST

Aerie bags an early OK for its self-described blockbuster glaucoma drug Rhopressa, recruiting 100 reps

John Carroll

Editor & Founder

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Large pharma companies spell out reasons why tariffs will harm US investments

Supreme Court to keep mulling state PBM dispute as US urges justices to decline case

Merck, Daiichi Sankyo scrap FDA application for HER3 ADC after survival miss

DNA giant Illumina spawned an ecosystem of competitors and customers

FDA rejects Stealth's rare disease drug, but offers potential for accelerated approval

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation